Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BI 885578 + Irinotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BI 885578||IGF-1R Inhibitor 17||BI 885578 is a dual inhibitor of insulin like growth factor-1 receptor (IGF1R) and insulin receptor (INSR) that blocks downstream signaling and leads to growth inhibition in tumor cells (PMID: 26438154, PMID: 28729397).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|